Eunice Wang, MD, of Roswell Park, discusses how the continued development of targeted therapies could improve the future treatment paradigm in acute myeloid leukemia. #leusm ow.ly/a6F350OTala

Claire F. Verschraegen, MD, The James, discusses adverse effects that are commonly associated with the use of single-agent nivolumab vs the combination of ipilimumab plus nivolumab in melanoma. #melsm ow.ly/6nw050OT9WJ

Jeffrey Zonder, MD, of Karmanos Cancer Institute, discusses the ongoing development of other BCMA-targeted and non–BCMA targeted bispecific antibodies in multiple myeloma, and how to navigate treatment decisions for patients eligible for CAR T-cell therapy. #mmsm ow.ly/JcIA50OTa91

Colin E. Champ, MD, of Allegheny Health, discusses findings from 2 clinical trials investigating boost radiotherapy plus whole breast radiotherapy following surgery in patients with ductal carcinoma in situ or early-stage breast cancer. #bcsm ow.ly/KRzF50OTapv

Bradley W. Christensen, MD, of Baylor Scott & White Health, discusses the process of patient selection for BCL-2 induction therapy in patients with acute myeloid leukemia in accordance with their individual disease characteristics. #leusm ow.ly/X4TX50OT9XQ

Stephen V. Liu, MD, of Georgetown Lombardi, discusses the activity of trastuzumab deruxtecan in patients with HER2-mutated non–small cell lung cancer. #lcsm ow.ly/1jcE50OT9ZT

Foluso Bisi Ademuyiwa, MD, MPH, MSCI, of Siteman Cancer Center, discusses the implications of the phase 3 KEYNOTE-522 trial in high-risk, early-stage triple-negative breast cancer. #bcsm ow.ly/xrHB50OTa4q

Christie J. Hilton, DO, Allegheny Health discusses the potential impact of the ongoing phase 2 CompassHER2-pCR trial for patients with HER2-positive breast cancer. #bcsm ow.ly/WMjp50OUtsw

Stephanie L. Graff, MD, of @LifespanHlthSys, gives an overview of recently approved ADCs in TNBC and HR-positive, HER2-negative breast cancer and the importance of continued research with these agents in the first-line setting. #bcsm ow.ly/slyF50OUtyV

Foluso Bisi Ademuyiwa, MD, MPH, MSCI, of Siteman Cancer Center, discusses the optimal sequencing of current CDK4/6 inhibitors in the first-line setting for hormone receptor–positive, HER2-negative breast cancer based on updated efficacy and safety data. #bcsm ow.ly/AaRT50OUtAW

Edgardo S. Santos, MD, FACP, @FAUMedSchool, discusses the impact of treatment with cemiplimab plus chemotherapy in patients with squamous non–small cell lung cancer. #lcsm ow.ly/yxv050OUtte

Marilyn Huang, MD, Sylvester Comprehensive Cancer Center, contextualizes findings within the endometrial cancer treatment landscape and emphasizes the unanswered questions regarding optimal therapies for patients with mismatch repair–proficient disease. #gynsm ow.ly/vmT050OUtPQ

Several landmark trials have led to FDA approval milestones across all breast cancer subtypes in the past 5 years, each continuing to change the navigation of treatment approaches in clinical practice. Siteman Cancer Center #bcsm ow.ly/Ft5s50OUtQ8

John L. Hays, MD, PhD, The James, discusses the evolution of the treatment paradigm for patients with metastatic colorectal cancer who experience disease progression following standard chemotherapy regimens. #crcsm ow.ly/GgE250OVcc0

Anne M. Noonan, MBBCh, The James, discusses recent practice-changing trials for the treatment of patients with hepatocellular carcinoma. #hcc #oncology ow.ly/uev450OVch3

Stephen V. Liu, MD, of Georgetown Lombardi, highlights the importance of next-generation sequencing in lung cancer, key trials that have shifted the NSCLC treatment landscape, and detailed ongoing research at his institution. #lcsm ow.ly/CSIL50OUtuU

Ernest S. Han, MD, PhD, of City of Hope, discusses the use of hyperthermic intraperitoneal chemotherapy in ovarian cancer. #ovca ow.ly/mTnB50OVcjm

Brian I. Rini, MD, FASCO, Vanderbilt-Ingram Cancer Center, discusses efforts to utilize genetic testing to improve treatment selection in renal cell carcinoma through the phase 2 OPTIC RCC trial. #kcsm ow.ly/9eip50OVcem

Manali Bhave, MD, of Winship Cancer Institute of Emory University, discusses the impact of new treatment strategies on the landscape of hormone receptor–positive/HER2-negative breast cancer. #bcsm ow.ly/IXo250OVckX

Don't worry! To continue to see live updates from our premier oncology-focused cancer care summits, follow us at OncLive.com.